Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Sarcoidosis affecting the lung parenchyma. It is characterized by the presence of non-necrotizing granulomas in the lung tissues. It is manifested with dyspnea, cough, fever, night sweats, fatigue, and weight loss.
Biomarker and diagnostic research for pulmonary sarcoidosis has been reported in the published literature.
10 clinical trials registered, 3 recruiting. Interventions under study include drug therapy, other interventions, and medical devices. Pipeline includes 1 PHASE4, 1 PHASE3, 4 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06853834](https://clinicaltrials.gov/study/NCT06853834) |
Data assembled from 3 of 12 sources · Last updated Nov 4, 2026, 3:11 PM UTC
Comparative Diagnostic Yield of Endobronchial Cryo Biopsy vs Forceps Biopsy in Patients With Suspected Sarcoidosis |
NA |
Sanjay Gandhi Postgraduate Institute of Medical Sciences |
RECRUITING |
[NCT06205121](https://clinicaltrials.gov/study/NCT06205121) | Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis | PHASE2 | Molecure S.A. | RECRUITING |
[NCT00001532](https://clinicaltrials.gov/study/NCT00001532) | Role of Genetic Factors in the Development of Lung Disease | — | National Heart, Lung, and Blood Institute (NHLBI) | RECRUITING |
207 publications have been identified in PubMed for pulmonary sarcoidosis. Kisho has analyzed 136 by research type. Research spans Review / Meta-Analysis (31%), Epidemiology / Natural History (27%), and Case Report / Case Series (17%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 42 | 31% |
Disease patterns and progression | 37 | 27% |
Patient case studies | 23 | 17% |
Testing and diagnosis research | 14 | 10% |
Clinical study results | 9 | 7% |
Laboratory research | 5 | 4% |
Other research | 4 | 3% |
New treatment approaches | 2 | 1% |
Zhao J (2026). [PMID: 41767532](https://pubmed.ncbi.nlm.nih.gov/41767532/). *Front Med (Lausanne)*. [Review / Meta-Analysis]
Van Den Blink B (2026). [PMID: 41819539](https://pubmed.ncbi.nlm.nih.gov/41819539/). *Eur Respir J*. [Clinical Trial Publication]
Kotti N (2026). [PMID: 41963075](https://pubmed.ncbi.nlm.nih.gov/41963075/). *BMJ Open Respir Res*. [Review / Meta-Analysis]
Wang S (2026). [PMID: 42164154](https://pubmed.ncbi.nlm.nih.gov/42164154/). *Front Med (Lausanne)*. [Case Report / Case Series]
Hashim Z (2026). [PMID: 42144146](https://pubmed.ncbi.nlm.nih.gov/42144146/). *Respir Med*. [Review / Meta-Analysis]
Ramos D (2026). [PMID: 41418888](https://pubmed.ncbi.nlm.nih.gov/41418888/). *Respir Med*. [Epidemiology / Natural History]
Ledda RE (2026). [PMID: 41406556](https://pubmed.ncbi.nlm.nih.gov/41406556/). *Curr Opin Immunol*. [Review / Meta-Analysis]
Dhanani Z (2026). [PMID: 42202746](https://pubmed.ncbi.nlm.nih.gov/42202746/). *Curr Opin Immunol*. [Review / Meta-Analysis]
Lotana H (2026). [PMID: 41519022](https://pubmed.ncbi.nlm.nih.gov/41519022/). *Curr Opin Immunol*. [Review / Meta-Analysis]
Yadav R (2026). [PMID: 41794119](https://pubmed.ncbi.nlm.nih.gov/41794119/). *Chest*. [Epidemiology / Natural History]
AI-curated news mentioning pulmonary sarcoidosis
Updated Oct 23, 2026
A national multicentre case-control study reveals distinct clinical presentations and prognoses for chronic beryllium disease compared to pulmonary sarcoidosis. This research enhances understanding of these conditions, potentially guiding future treatment approaches.
Recent research highlights the potential of quantitative computed tomography imaging to enhance the assessment of pulmonary sarcoidosis. This approach may improve diagnostic accuracy and monitoring of disease progression.